A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
← catalyst calendarNCT05951959 · readout in 804 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
108actual
Sites
29
Countries
Australia, Brazil, Canada +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-13 | actual | When the study began enrolling |
| Primary completion | 2028-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mantle Cell Lymphoma (MCL)
Interventions
- Drug: Acalabrutinib — also filed as Acalabrutinib, CALQUENCE
- Drug: Venetoclax
- Drug: Rituximab
Primary outcome
what the primary-completion date above is the date OFMRD-negative CR rate
measured At the end of AVR induction, i.e., following completion of Cycle 13 (each cycle is 28 days)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed